Sources

These are the sources behind the health claims in our articles. Numbers in the articles link here.

How we handle claims

We prefer guidelines and trial results over blog posts, and we say when we're relying on a secondary report. Surveys run by companies with a product to sell are labeled as such. If a figure is an estimate or comes from a limited study, the article says so. Product details (ingredients, prices, serving sizes) come from manufacturers' product pages and retailer listings, and prices change.

References

1. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity, 2025. doi:10.1002/oby.24336. Link

Used for: preserving muscle with resistance training and diet during GLP-1 therapy.

2. Healio, "Sustainable success with GLP-1s requires guided nutrition, lifestyle strategies" (Sept. 22, 2026). Reports the advisory's protein recommendation of 1.2 to 1.6 g per kg of healthy body weight and the tip of setting goals per meal and snack. Link

Used for: the protein range. We cite this report because we read the figure there; check the advisory itself for the full context.

3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021.

Used for: average weight loss of about 15% over 68 weeks.

4. Wilding JPH, et al. Impact of semaglutide on body composition in adults with overweight or obesity: STEP 1 DXA substudy. Presented at ENDO 2021 (Endocrine Society press release). Link

Used for: lean body mass fell 9.7% while total weight fell 15.0%. The roughly 40% lean share of weight lost is calculated from these figures by independent reviews.

5. Look M, et al. SURMOUNT-1 DXA substudy of tirzepatide. Diabetes, Obesity and Metabolism, 2025, as summarized by secondary reviews.

Used for: roughly 25% of weight lost registered as lean mass with tirzepatide. We have not read the full paper.

6. Barbell Medicine, "GLP-1s and muscle loss: what the evidence shows." Link

Used for: DXA "lean mass" includes water and organ tissue, so it overstates muscle loss.

7. Patient Care Online, "Muscle loss during GLP-1 therapy top concern for patients using the antiobesity medications" (survey of 1,000 U.S. adults on GLP-1s, run by Veru). Also covered by Fierce Pharma. Link

Used for: 36% rated their muscle-loss risk moderate to very high, behind digestive (50%) and neurologic (44%) concerns. The sponsor develops a muscle-preserving drug.

8. ukactive, GLP-1 medications and muscle mass preservation: implications and recommendations (Dec. 2025). Link

Used for: resistance training 2-3 times a week, noting that research on exact protocols for GLP-1 users is limited, and that lean-mass loss is comparable to bariatric surgery.

9. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. Figures as summarized by JumpstartMD. Link

Used for: 17.3% average loss, 11.6 points regained, 5.6% net loss one year after stopping.

10. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 2023. Figures as summarized by JumpstartMD. Link

Used for: about 21% lead-in loss, 14.0% regain on placebo, further 5.5% loss with continued treatment.

11. 2026 BMJ meta-analysis of 37 studies and 9,341 people on weight regain after stopping semaglutide or tirzepatide, as summarized by JumpstartMD. We have not read the original paper. Link

Used for: regain of about 0.8 kg per month.

12. Cleveland Clinic retrospective cohort of 7,938 patients who stopped semaglutide or tirzepatide after 3 to 12 months, reported by Drug Topics. Link

Used for: smaller regain in a real-world cohort with less weight lost and shorter treatment.

13. Robard Biocare2 launch coverage (Prepared Foods) and a wholesale product listing describing the formula. Link

Used for: the manufacturer's description of Biocare2. No independent evidence reviewed.

14. Healthline, "Staying hydrated while taking GLP-1s." Link

Used for: reduced thirst, when to contact your care team, fluids from food, electrolyte drinks during vomiting or diarrhea.

15. New Atlas, "New kidney injury warnings added to all GLP-1 drugs by FDA." Link

Used for: FDA label updates warning that dehydration from GI side effects can cause kidney injury, and early warning signs.

16. Pillo, "How much water to drink on a GLP-1 medication," which cites the 2025 Nephrology Dialysis Transplantation pooled analysis of 12 trials (36,568 participants). Link

Used for: no significant overall increase in acute kidney injury in pooled trials. We have not read the original analysis.

If you spot a claim that needs a better source, tell me.